non-small cell lung cancer
Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug
The companies will jointly develop and commercialize Guardant360 CDx and Guardant360 TissueNext for taletrectinib treatment in advanced and metastatic NSCLC.
Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test
The firms will develop the NGS-based CDx for non-small cell lung cancer drug Tagrisso using the Oncomine Dx Express Test on the Genexus Dx System.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.
FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
Japanese Lung Cancer Genomic Screening Project Expands in Asia-Pacific
LC-SCRUM-Asia, a genomic screening project and database that initially launched in Japan in 2013, is expanding and will cover additional countries in the Asia-Pacific region.